MAP2K7 and melanoma: No increase in overall adverse events (AEs), grade 3/4 AEs, and severe adverse events (SAEs) was observed between the cohorts.<h4>Conclusions</h4>BRAF inhibitors (plus MEK inhibitor) may achieve better intracranial disease stability in BRAF-mutant melanoma patients who have received previous local treatment for BMs.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/prospero/), identifier CRD42020185984.